Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
Date:5/9/2008

CALGARY, May 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

"We are hopeful that this trial will provide more information on how we might improve the effectiveness of this promising new approach to treating cancer," said Dr. Spicer.

"In animal models, pretreatment with low-dose immune modulators has been shown to significantly enhance the antitumour activity of REOLYSIN(R)(ref.)," added Dr. Brad Thompson, President and CEO of Oncolytics. "This study will help confirm if this can also be achieved in humans. If it can, it could lead to exciting opportunities to expand the use of REOLYSIN(R) for cancer treatment."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objectives of the trial include determining the Minimum Effective Immunomodulatory Dose (MED) of cyclophosphamide to obtain successful immune modulation. Secondary objectives include determining the safety profile of the combination and gathering any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

Ref:

Clin. Cancer Res. 2008 14:259-269

Cancer Gene Ther. 2006 Aug; 13(8): 815-8

Cancer Res, 2003 Jan 15; 63(2):348-53

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R)/cyclophosphamide clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
2. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
3. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
4. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
5. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
8. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
9. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
10. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its ... tumors to grow on nerves throughout the body. It affects 1 in 3,000 people ... events held during the month of May, as well as online activities, Neurofibromatosis Awareness ...
(Date:5/3/2016)... , May 3, 2016 ... (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD ... (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, ... MarketsandMarkets, the market is expected to reach ... 7.63 Billion in 2015, growing at a ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader ... to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories ... and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas ... surgeon in The Woodlands, Texas , ... 24 percent of treated fat cells in just 25-minutes, ... Close to 90 percent of Americans report feeling bothered ... Nonsurgical fat reduction procedures are a growing industry. This ...
Breaking Biology Technology:
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
Breaking Biology News(10 mins):